期刊
CURRENT PHARMACEUTICAL DESIGN
卷 18, 期 20, 页码 2921-2935出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/138161212800672732
关键词
Selective; VEGFR inhibitor; anticancer; angiogenesis
资金
- Ministry of Science and Technology of China [2012ZX09506001-010, 2012CB722605, 2012AA020305, 2011DFA30620]
Angiogenesis and vasculogenesis, regulated by VEGF/VEGFR signaling pathways, play key roles in tumor growth and metastasis. Selective inhibition of VEGFR kinase has been explored as a highly successful clinical strategy in cancer treatment. A number of VEGFR inhibitors have been approved in clinical use and many more are in various stages of drug development. This paper reviews selective small-molecule VEGFR inhibitors in clinical uses and in clinical trials, with particular focus on in vitro, in vivo and clinical trial results of these inhibitors. The VEGF/VEGFR genes and signaling pathways involved in tumor angiogenesis, and the strategies for accessing and improving the therapeutic efficacy of VEGFR inhibitors are also discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据